Sophia Antipolis, France

MEDIAN Technologies has been selected to manage medical images in a phase II clinical study for lung cancer sponsored by a global Top 10 pharmaceutical company

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today that it has been selected to provide imaging solutions and services in a new phase II clinical trial for Non-Small Cell Lung Cancer. The study is sponsored by a major global biopharmaceutical company.

Within the framework of the project, imaging data will be acquired from 20 clinical sites worldwide. Anticipated total enrollment is 50 patients with a forecasted start date early 2014. MEDIAN will provide on-site reading services based on the deployment of its MEDIAN LMS -Lesion Management Solutions- application software. MEDIAN LMS is a suite of software modules for the automated detection, quantification, and tracking of tumors in 3D medical images. It provides unique features for the review of images and quantitative assessment of response to therapy in clinical trials. Within the frame of the trial, response evaluation to therapy will be assessed using RECIST criteria and tumor volume growth, an advanced imaging biomarker. MEDIAN will also supply a set of services including clinical site training, as well as collection and quality control of image interpretations performed by the sites involved in the study.

The anticipated amount for the project is € 205,000 (eq. $ 267,000).

“We have worked with this global top 10 pharmaceutical company since the creation of our imaging services offer to the pharmaceutical industry”,said Nicolas Dano, Director of Business Development, Europe and Asia. “Having this third consecutive study awarded with them demonstrates the relevance of our approach regarding the management of images in clinical trials as well as the quality of our services”.

Since the beginning of 2013, MEDIAN Technologies has recorded €4.7M of orders, including €1,0M of firm orders and €3.7M of project awards [*].

[*] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.

Download Project_award_dec12.pdf

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”


MEDIAN Technologies

Fredrik Brag
+33 4 92 90 65 82

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66